The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery

PURPOSE: Bariatric surgery is nowadays commonly applied as treatment for morbid obesity (BMI > 40 kg/m(2)). As information about the effects of this procedure on a drug’s pharmacokinetics is limited, we aimed to evaluate the pharmacokinetics of CYP3A probe substrate midazolam after oral and intra...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pharm Res
Auteurs principaux: Brill, Margreke J., van Rongen, Anne, van Dongen, Eric P., van Ramshorst, Bert, Hazebroek, Eric J., Darwich, Adam S., Rostami-Hodjegan, Amin, Knibbe, Catherijne A.
Format: Artigo
Langue:Inglês
Publié: Springer US 2015
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4628089/
https://ncbi.nlm.nih.gov/pubmed/26202517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11095-015-1752-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires